Biogen Inc. (BIIB)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
As of 01:20PM EDT. Market open.
| Previous Close | 202.46 |
| Open | 201.22 |
| Bid | 208.98 x 100 |
| Ask | 209.57 x 100 |
| Day's Range | 199.10 - 209.46 |
| 52 Week Range | 189.44 - 319.76 |
| Volume | |
| Avg. Volume | 1,260,329 |
| Market Cap | 30.466B |
| Beta (5Y Monthly) | -0.01 |
| PE Ratio (TTM) | 26.16 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
- Zacks
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
- GuruFocus.com
Decoding Biogen Inc (BIIB): A Strategic SWOT Insight
Insightful Analysis of Biogen Inc's Financials and Strategic Positioning
© 2024 Yahoo. All rights reserved.